NCT06042985

Brief Summary

The precise impact of calcium absorption in relation to RYGB, SG, and OAGB remains under-researched in terms of statistical power and the diversity of BMS procedures considered. Therefore, this presents a critical area for future investigation to improve patient outcomes in BMS.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Dec 2023

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 14, 2023

Completed
1 month until next milestone

First Posted

Study publicly available on registry

September 21, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

December 1, 2023

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2024

Completed
Last Updated

September 21, 2023

Status Verified

September 1, 2023

Enrollment Period

4 months

First QC Date

August 14, 2023

Last Update Submit

September 15, 2023

Conditions

Keywords

Calcium Citratebariatric surgeryAbsorptionCalcium Carbonate

Outcome Measures

Primary Outcomes (3)

  • Elemental Calcium effects in blood serum (Peak Plasma Concentration (Cmax))

    In patients who have undergone bariatric surgery and are receiving elemental calcium supplementation in the form of citrate or carbonate, we observe variations in their blood serum with peak concentrations (Cmax) These changes provide insights into how effectively the body absorbs and utilizes calcium following supplementation.

    8 hours

  • Elemental Calcium effects in Urine excretion (time curve (AUC))

    In patients who have undergone bariatric surgery and are receiving elemental calcium supplementation in the form of citrate or carbonate, we observe variations in their cumulative excretion of urinary calcium over time (AUC). These changes provide insights into how effectively the body absorbs and utilizes calcium following supplementation.

    8 hours

  • Elemental Calcium effects in blood serum (Area under the plasma concentration)

    In patients who have undergone bariatric surgery and are receiving elemental calcium supplementation in the form of citrate or carbonate, we observe variations in their blood serum with Area under the plasma concentration (AUC) These changes provide insights into how effectively the body absorbs and utilizes calcium following supplementation.

    8 hours

Study Arms (3)

RYGB arm: calcium citrate and calcium carbonate

ACTIVE COMPARATOR

The absorption effect between calcium citrate and calcium carbonate in patients with a RYGB

Drug: The absorption effect between calcium citrate and calcium carbonate

LSG arm: calcium citrate and calcium carbonate

ACTIVE COMPARATOR

The absorption effect between calcium citrate and calcium carbonate in patients with a LSG

Drug: The absorption effect between calcium citrate and calcium carbonate

OAGB arm: calcium citrate and calcium carbonate

ACTIVE COMPARATOR

The absorption effect between calcium citrate and calcium carbonate in patients with a OAGB

Drug: The absorption effect between calcium citrate and calcium carbonate

Interventions

Elemental Calcium citrate supplementation will significantly improve patients' absorption after BMS in all cases.

Also known as: Elemental Calcium citrate, Elemental Calcium Carbonate, Chewable tablets
LSG arm: calcium citrate and calcium carbonateOAGB arm: calcium citrate and calcium carbonateRYGB arm: calcium citrate and calcium carbonate

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients aged 18-75 years old
  • After BMS surgery who had an RYGB, SG, or OAGB operation at least 12 months before the study.
  • Patients will be selected at random from the hospital's electronic patient system.

You may not qualify if:

  • Patients on antacids during the study
  • Patients onH2 receptor antagonists during the study
  • Patients on proton pump inhibitors during the study
  • Patients with a previous oophorectomy,
  • Liver disease,
  • Renal disease,
  • Hypercalcemia,
  • Hyperthyroidism,
  • Hypothyroidism who require levothyroxine supplementation (Levothyroxine forms complexes with calcium)
  • Parathyroid disorders
  • Use of diuretics,
  • Use of calcitonin,
  • Use of corticosteroids,
  • Use of anabolic steroids,
  • Use of anticonvulsants within three months of the study
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The surgical department of Medical Research Institute Hospital, Alexandria University

Alexandria, Egypt

Location

Related Publications (5)

  • Allied Health Sciences Section Ad Hoc Nutrition Committee; Aills L, Blankenship J, Buffington C, Furtado M, Parrott J. ASMBS Allied Health Nutritional Guidelines for the Surgical Weight Loss Patient. Surg Obes Relat Dis. 2008 Sep-Oct;4(5 Suppl):S73-108. doi: 10.1016/j.soard.2008.03.002. Epub 2008 May 19. No abstract available.

    PMID: 18490202BACKGROUND
  • Mechanick JI, Apovian C, Brethauer S, Garvey WT, Joffe AM, Kim J, Kushner RF, Lindquist R, Pessah-Pollack R, Seger J, Urman RD, Adams S, Cleek JB, Correa R, Figaro MK, Flanders K, Grams J, Hurley DL, Kothari S, Seger MV, Still CD. CLINICAL PRACTICE GUIDELINES FOR THE PERIOPERATIVE NUTRITION, METABOLIC, AND NONSURGICAL SUPPORT OF PATIENTS UNDERGOING BARIATRIC PROCEDURES - 2019 UPDATE: COSPONSORED BY AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY, THE OBESITY SOCIETY, AMERICAN SOCIETY FOR METABOLIC & BARIATRIC SURGERY, OBESITY MEDICINE ASSOCIATION, AND AMERICAN SOCIETY OF ANESTHESIOLOGISTS - EXECUTIVE SUMMARY. Endocr Pract. 2019 Dec;25(12):1346-1359. doi: 10.4158/GL-2019-0406. Epub 2019 Nov 4.

    PMID: 31682518BACKGROUND
  • Tondapu P, Provost D, Adams-Huet B, Sims T, Chang C, Sakhaee K. Comparison of the absorption of calcium carbonate and calcium citrate after Roux-en-Y gastric bypass. Obes Surg. 2009 Sep;19(9):1256-61. doi: 10.1007/s11695-009-9850-6. Epub 2009 May 13.

    PMID: 19437082BACKGROUND
  • Smelt HJ, Pouwels S, Smulders JF. The Clinical Dilemma of Calcium Supplementation After Bariatric Surgery: Calcium Citrate or Calcium Carbonate That Is the Question? Obes Surg. 2016 Nov;26(11):2781-2782. doi: 10.1007/s11695-016-2346-2. No abstract available.

    PMID: 27558620BACKGROUND
  • Schafer AL, Weaver CM, Black DM, Wheeler AL, Chang H, Szefc GV, Stewart L, Rogers SJ, Carter JT, Posselt AM, Shoback DM, Sellmeyer DE. Intestinal Calcium Absorption Decreases Dramatically After Gastric Bypass Surgery Despite Optimization of Vitamin D Status. J Bone Miner Res. 2015 Aug;30(8):1377-85. doi: 10.1002/jbmr.2467. Epub 2015 May 21.

MeSH Terms

Interventions

Calcium Carbonate

Intervention Hierarchy (Ancestors)

Calcium CompoundsInorganic ChemicalsCarbonatesCarbonic AcidCarbon Compounds, InorganicMinerals

Study Officials

  • M Hany Ashour, MD

    Alexandria University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
All the patients will be used in a cross-over study design. The same patient will be using study drugs A or B and switching in the study to the other drug. 7 days period will be applied for any wash-out or possible carry-over effect.
Purpose
TREATMENT
Intervention Model
CROSSOVER
Model Details: In a double-blind-randomization procedure, surgeons, the research team, the laboratory, and the statistical analysis team will be blinded; the patient has no influence and not necessary to be blind.
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

August 14, 2023

First Posted

September 21, 2023

Study Start

December 1, 2023

Primary Completion

April 1, 2024

Study Completion

June 1, 2024

Last Updated

September 21, 2023

Record last verified: 2023-09

Data Sharing

IPD Sharing
Will share

The analysis will be performed on a blinded dataset after completing the medical/scientific review. All protocol violations will be identified and resolved, and the dataset will be declared complete. All data will be collected in a data management system (Castor EDC, Amsterdam, The Netherlands; https://www.castoredc.com), handled according to Good Clinical Practice guidelines, Data Protection Directive certificate, and complied with Title 21 CFR Part 11. Furthermore, the data centers where all the research data will be stored are certified according to ISO27001, ISO9001, and Dutch NEN7510.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
after study completed, for 15 years
Access Criteria
contact study PI

Locations